Lab Research (LRI) aims to boost its Korean presence in a new agency deal with Safe Chemicals that, CEO Luc Mainville says, will meet growing demand for large molecule contract R&D.
QPS’ bioanalytical laboratory in Taiwan is the first in the country to be certified as compliant with good laboratory practice (GLP) standards by the Department of health (DoH), according to unit president Vincent Yen.
Pharma companies can cut the risk of taking a TKI into Phase I by using the HemoRANK in vitro test, according to ReachBio that has developed the assay to evaluate a molecules clinical hematotoxicity.
In 25 years most biotechs will be virtual, according to a director of preclinical CRO L2D who formed the company with a “completely novel business model” to target this huge growth opportunity.
US contract research organisation (CRO) PPD has set its sights on the Asian biopharma sector with new a lab at the heart of Singapore’s rapidly expanding drug development and trial industry.
Outsourcing to a well known CRO with a good reputation is vital to ensuring that data is well received by regulatory authorities, according to a CEO that just inked a deal for preclinical safety testing.
US firms Xybion Medical Systems and Locus Technology say their new animal management and data analysis partnership will help streamline preclinical development and reduce research costs.
Biotechs that partner or outsource in emerging markets are better equipped to innovate and prosper, according to research that warns “if you are not in Shanghai, Mumbai, or Dubai, watch out".
US contract research organisation (CRO) Advion BioServices has expanded its biomarker business in an effort to meet growing industry demand for pharmacological analysis.
The outsourcing “market is poised to return to healthier growth rates in 2010”, according to the president of MDS Pharma Services who also told Outsourcing-Pharma that CROs will play an increasingly important role in drug development.
Aushon BioSystems has added laboratory and manufacturing capacity to its corporate headquarters to meet rising demand from clinical trials for some of its protein biomarker services.
US discovery chemistry contractor ChemBridge has made some of its most popular small molecule libraries available on-line through a partnership with preclinical data specialist Collaborative Drug Discovery (CDD).
Transcrip Partners’ “augmentation” solution for contract R&D “differs from the normal consultancy alternative by fielding ‘doers’ who can think strategically and ‘thinkers’ who are happy to get their hands dirty” according to senior partner Paul Branthwaite.
New multi-million dollar R&D contracts with top three pharma and biotech players go someway to “alleviating” the negative impact of downturn, according to Lab Research CEO Luc Mainville.
US CRO and central laboratory services provider Pacific Biometrics (PBI) has entered into a $4m (€2.7m) loan agreement that it says will help further the development of its contract biomarkers business.
By acquiring a stake in India-based RSIPL Evotec believes it can offer clients quicker drug development services, an important aspect of coping with attrition, because larger teams of chemists are available in emerging markets.
Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its Nordion business.
Summit has sold Dextra, its analytical and manufacturing services division, to NZP but believes operating the contract business has been beneficial to its industry standing and R&D capabilities.
US firm PerkinElmer has opened a second plant to meet growing demand for radiolablled compounds for ADME and, it hopes, ultimately help drugmakers make go/no go development decisions earlier.
Demand for Cerep’s pharmacological profiling services picked up in the second quarter and it believes this, coupled to cost savings and commencement of delayed contracts, will help it improve in the second half of 2009.
Source BioScience (SBS) is eyeing acquisitions and investments in technology after it posted a profit in the first six months of 2009, overturning a loss in the same period of last year.
Sigma-Aldrich is using a novel methodology to create rats with targeted gene deletion in as little as four months, which it believes could eliminate years of research and improve drug development.
PCAS is setting up a kilolab in California, US to target the small-scale synthesis market, which it believes will benefit its large-scale operations by establishing relationships earlier in development.
US CRO Covance has delayed the construction of a proposed $145m (€102m) preclinical toxicology testing facility at a 47 acre site at the Prince William Technology Park in Virginia.
The British pound’s weakness compared to other EU currencies is benefiting UK-based CROs, according to Lab Research (LRI), which attributed the poor performance of its Danish business to the exchange rate.
Wuxi PharmaTech’s China-based laboratory services grew by 23 per cent in Q2, outstripping expectations and resulting in the company revising its guidance for the business segment.
India’s outsourcing sector is growing at 43 per cent, according to a new report that predicts the country will take a bigger share of the global market as concerns about operating there diminish.
Millipore has expanded its European biotech services business by acquiring BioAnaLab, a UK-based company that provides analysis of biologics and vaccines.
The threat posed by animal rights activists has been highlighted by an alleged arson attack on the Novartis’ CEO’s lodge, with one group saying their only regret is that he was not home when it burned.
Life Sciences Research’s (LSR) operating income fell by 60 per cent to $4m (€2.8m) in Q2 but believes that the contract research market will improve later this year or in 2010.
Ecron Acunova’s global partnering team had a busy end to July with the Indian CRO entering into collaboration deals on both sides of the Atlantic to further expand its global reach.
In response to rising demand from the pharma industry NeuroScience Associates (NSA) is opening a new laboratory that will quadruple capacity for its brain and spinal cord histology services.
US private equity group Water Street Healthcare Partners (WSHP) says its purchase of AAIPharma’s pharmaceutical development business was a “unique opportunity” to invest in an expanding market.
The Oxford, UK, biomarker laboratory facilities of India’s Veeda CR have been taken over by Icon Development Solutions, in a deal which both consolidates existing customer relationships for the buyer and opens up new product areas to focus on.
US contract research organisation (CRO) QPS has been called in by the Taiwanese Development Center for Biotechnology (DCB) to provide support services for biotech firms operating in the region.
India and China share many similarities as outsourcing locations but there are also significant differences that are important to understand before making a commitment, according to a report.
US CRO Charles River (CRL) has unveiled a raft of executive changes and plans to restructure its PCS unit to provide customers with a more centralised approach to global drug development.
Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
US contractor Velesco Pharmaceutical Services has leased a new clinical trial materials manufacturing facility in Kalamazoo, Michigan, extending its range of preclinical and early trial development services.
MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.
Canadian CRO MDS Pharma Services (MDS) is to sell its Phase II-IV trial business to US counterpart INC Research for $50m (€35m) and focus on providing discovery and early clinical development services.
BioTrove is taking aim at the drug development sector with its RapidFire 300 absorption, distribution, metabolism, and elimination (ADME) screening system that, it claims, can analyse samples in a fraction of the time taken by traditional HPLC.
Power outages cost India $9.2bn (€6.5bn) in 2008, according to a report, with the disruptions causing direct losses in numerous sectors, including pharma and biotech.
There has been “tremendous interest” in Fate Therapeutics’ Catalyst programme, which gives access to induced iPS cell technology as part of collaborative relationship between numerous companies.
Outsourcing-Pharma met with Charlesson to discuss the company’s business model, which sees its in-house activities benefit from revenues, experience and contacts generated by its preclinical service offering.
The Norway-based company was spun out of Bergen University a few months ago but its tools, which it believes give more information on a target than any other currently available tech, have already attracted interest from biotechs in Europe, the US and...
The use of internal standards (IS) is essential for developing and applying liquid chromatography-tandem mass spectrometric (LC-MS/MS) quantitative bioanalytical...
Global regulatory standards govern bioanalytical method development, validation and the subsequent assays. When those standards are updated, industry stakeholders...
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...
